Stock Track | Autolus Therapeutics Soars 9.7% in Pre-Market on Analyst Upgrade and FDA Approval Prospects

Stock Track

Nov 18, 2024

Autolus Therapeutics PLC (AUTL) saw its stock soar 9.7% in pre-market trading on Monday, following positive analyst coverage and anticipation of FDA approval for one of its drug candidates.

Goldman Sachs upgraded Autolus Therapeutics to a "Buy" rating from "Neutral" and raised its price target to $7.60, citing the potential approval of the company's lead drug candidate Aucatzyl. Analyst Rajan Sharma noted that FDA approval of Aucatzyl would de-risk Autolus' platform and could lead to significant upside for the stock.

Additionally, analysts polled by Capital IQ have an average "Buy" rating on Autolus Therapeutics, with price targets ranging from $7 to $13, indicating further upside potential if the company's pipeline progresses favorably.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Trading app for stocks, options & ETFs","description":"Invest in US, ASX, HK, China A-shares, ETFs & options with Tiger Brokers, Australia's trusted stock trading app!","keywords":"tiger brokers,tiger brokers au,tiger brokers australia,tiger trade,tiger trading,australia stock platform,US option,US stocks,stocks and options,australian trading platform,online broker australia,stock trading apps,mobile trading app,desktop trading,chess sponsored brokers,share trading platform","social":{"ogDescription":"Invest in US, ASX, HK, China A-shares, ETFs & options with Tiger Brokers, Australia's trusted stock trading app!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1148503177"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"AUS","license":"TBAU","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1148503177\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1148503177?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-18 21:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1148503177","market":"us","top_or_hot":-1,"title":"Stock Track | Autolus Therapeutics Soars 9.7% in Pre-Market on Analyst Upgrade and FDA Approval Prospects","media":"Stock Track","content":"<p>Autolus Therapeutics PLC (AUTL) saw its stock soar 9.7% in pre-market trading on Monday, following positive analyst coverage and anticipation of FDA approval for one of its drug candidates.</p>\n\n<p>Goldman Sachs upgraded Autolus Therapeutics to a \"Buy\" rating from \"Neutral\" and raised its price target to $7.60, citing the potential approval of the company's lead drug candidate Aucatzyl. Analyst Rajan Sharma noted that FDA approval of Aucatzyl would de-risk Autolus' platform and could lead to significant upside for the stock.</p>\n\n<p>Additionally, analysts polled by Capital IQ have an average \"Buy\" rating on Autolus Therapeutics, with price targets ranging from $7 to $13, indicating further upside potential if the company's pipeline progresses favorably.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Autolus Therapeutics Soars 9.7% in Pre-Market on Analyst Upgrade and FDA Approval Prospects</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Autolus Therapeutics Soars 9.7% in Pre-Market on Analyst Upgrade and FDA Approval Prospects\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2024-11-18 21:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Autolus Therapeutics PLC (AUTL) saw its stock soar 9.7% in pre-market trading on Monday, following positive analyst coverage and anticipation of FDA approval for one of its drug candidates.</p>\n\n<p>Goldman Sachs upgraded Autolus Therapeutics to a \"Buy\" rating from \"Neutral\" and raised its price target to $7.60, citing the potential approval of the company's lead drug candidate Aucatzyl. Analyst Rajan Sharma noted that FDA approval of Aucatzyl would de-risk Autolus' platform and could lead to significant upside for the stock.</p>\n\n<p>Additionally, analysts polled by Capital IQ have an average \"Buy\" rating on Autolus Therapeutics, with price targets ranging from $7 to $13, indicating further upside potential if the company's pipeline progresses favorably.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AUTL","symbol_name":"Autolus Therapeutics PLC","start_time":0,"source_url":"","article_id":"1148503177","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1148503177","pubTimestamp":1731934934,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Autolus Therapeutics PLC  saw its stock soar 9.7% in pre-market trading on Monday, following positive analyst coverage and anticipation of FDA approval for one of its drug candidates.Goldman Sachs upgraded Autolus Therapeutics to a \"Buy\" rating from \"Neutral\" and raised its price target to $7.60, citing the potential approval of the company's lead drug candidate Aucatzyl. Analyst Rajan Sharma noted that FDA approval of Aucatzyl would de-risk Autolus' platform and could lead to significant upside","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"AUTL":"Autolus Therapeutics PLC"},"translate_title":"由于分析师升级和FDA批准前景，股票跟踪Autolus Therapeutics盘前飙升9.7%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AUTL":1},"content_text":"Autolus Therapeutics PLC (AUTL) saw its stock soar 9.7% in pre-market trading on Monday, following positive analyst coverage and anticipation of FDA approval for one of its drug candidates.\nGoldman Sachs upgraded Autolus Therapeutics to a \"Buy\" rating from \"Neutral\" and raised its price target to $7.60, citing the potential approval of the company's lead drug candidate Aucatzyl. Analyst Rajan Sharma noted that FDA approval of Aucatzyl would de-risk Autolus' platform and could lead to significant upside for the stock.\nAdditionally, analysts polled by Capital IQ have an average \"Buy\" rating on Autolus Therapeutics, with price targets ranging from $7 to $13, indicating further upside potential if the company's pipeline progresses favorably.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}